10/14/11 Contest Update
Call it the Herman Cain rally. As Michele Bachmann astutely pointed out, when you turn Cain’s 999 plan upside down, “the devil is in the details.” And who but the devil would be so cruel to the shorts?
At Friday’s close, the NBI was up 4.32% YTD (vs. up .74% YTD a week ago) and the Contest median was down -5.27% YTD (vs. down -10.12% YTD a week ago). The Nasdaq Composite Index was up .56% YTD (vs. down -6.54% YTD a week ago).
Our leader JIBAC’s portfolio (up 48.74% YTD) had a terrific week and pulled away from the pack. MCBIO’s portfolio (up 37.43% YTD) took over second place and GENE’s portfolio (up 35.11% YTD) slipped back to third place.
At Friday's close, 14 of the 38 Contest portfolios were in the black, while 10 were beating the NBI.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week (foreign stock prices are not converted to US$ in these two tables).
Portfolio adjustments: None
Have a wonderful weekend biotechies!
(All corrections, especially adjustments for splits, greatly appreciated.)
10/14/11
Rank Name Profit/Loss
1 JIBAC 48,735
2 MCBIO 37,434
3 GENE 35,110
4 ROCKY 33,572
5 FIB 31,288
6 RRGE 21,164
7 BIOFISH 7,260
8 JULIUS 6,769
9 IJF 5,284
10 BIOJIM 5,247
Week's Top 5 Gainers
Symbol 10/7 10/14 % change
CBPO 6.38 9.68 51.72%
ACHN 4.42 5.82 31.67%
DVAX 1.83 2.39 30.60%
PACB 3.00 3.87 29.00%
MITI 4.77 6.09 27.67%
Week's Top 5 Losers
Symbol 10/7 10/14 % change
ROSG 1.07 0.82 -23.36%
ALTH 1.75 1.52 -13.14%
DEPO 5.45 4.94 -9.36%
NRGX.OB 0.55 0.50 -9.09%
TLON.OB 0.72 0.66 -8.33% |
